Sign Out
Pregnant women: This product should be used in pregnant women or women who may be pregnant only if the expected therapeutic benefits outweigh the possible risks associated with treatment. [The safety of this product during pregnancy has not been established. Reproduction studies have been performed in rabbits. In the study of administration during organogenesis in rabbits, increased incidences of abortion and late resorption and reduce in fetal weight were observed when latanoprost was given by intravenous administration at a dose that was approximately 80 times the clinical dose (5 μg/kg/day).]
Nursing mothers: Administration of this product should be avoided in breastfeeding mothers. If the use of this product is unavoidable, the patient should discontinue breastfeeding. [An animal study (in rats, i.v.) has shown that the drug was excreted in breast milk.]
